Gout is the chronic disease characterized by pain and inflammation in the joint. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of the needle-like crystals in the joints resulting into inflammation and pain. The conditions can be treated or prevented with use of the drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout for certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.
Market Dynamics
Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the gout disease treatment market growth in forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017–2018 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.
Key features of the study:
- This report provides in-depth analysis of the global gout disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019 – 2027), considering 2018, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
- This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles leading players in the global gout disease treatment market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences
- Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
- The global gout disease treatment market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global ophthalmic viscoelastic devices industry, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Gout Disease Treatment Market, By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- Global Gout Disease Treatment Market, By Route of Administration:
- Global Gout Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Gout Disease Treatment Market, By Region:
- North America
- By Country:
- By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- By Route of Administration:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- By Route of Administration:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- By Route of Administration:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- By Route of Administration:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- By Route of Administration:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Class:
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Colchicine
- Urate-lowering Agents
- Monoclonal Antibody
- By Route of Administration:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- AstraZeneca Plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Takeda Pharmaceutical Company Limited
- Novartis International AG
- Teijin Pharma Limited
- Simcere Pharmaceutical
- JW Pharmaceutical Corporation
- Horizon Therapeutics plc
- Hikma Pharmaceuticals Plc.
- Ironwood Pharmaceuticals, Inc.
- CymaBay Therapeutics, Inc.
- Zyla Life Sciences
“*” marked represents similar segmentation in other categories in the respective section
